The drug is expected to cater to the fast growing Rheumatoid Arthritis, Plaque Psoriasis, JIA, Psoriatic Arthritis, Ankylosing Spondylitis, Ulcerative Colitis, Crohns disease, HS and Uveitis markets
GlobalData’s ‘Pharmaceutical Intelligence Center’ observes that India is still in the nascent stage of developing these potential therapies as currently only four cell/gene therapy molecules are being developed in the country.
Company raises the annual revenue guidance from mid-teens to high teens
Syngene's collaboration with Zoetis started in 2011
This is the 142nd ANDA (including 8 tentative approvals received) out of Eugia Pharma Specialty Group (EPSG) facilities, manufacturing both oral and sterile specialty products.
Safety in these pediatric populations was consistent with the known safety profile across approved adult and pediatric indications1,2
Silo enters into commercial evaluation license agreement for next generation liposomes
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Motrin Oral Suspension, 100 mg/5 mL, of McNeil Consumer Healthcare (McNeil)
The aim is to provide further insights into patients' lives in the effort to deliver better outcomes for people with psoriatic arthritis (PsA)
The hybrid congress will take place from 1-4 June in Copenhagen, as well as virtually
Subscribe To Our Newsletter & Stay Updated
